From: Downregulated SPINK4 is associated with poor survival in colorectal cancer
Datasets | Variable | Group | HR | (95% CI) | Â | P value |
---|---|---|---|---|---|---|
GSE24551 dataset | Univariate analysis | Â | Â | Â | Â | Â |
 TNM stage | (III vs. II) | 1.966 | 1.190 | 3.246 | 0.008 | |
 Microsatellite status | (MSI-H vs. MSS, MSI-L) | 0.246 | 0.077 | 0.786 | 0.018 | |
 SPINK4 expression | (high vs. low) | 0.413 | 0.188 | 0.906 | 0.027 | |
Multivariate analysis | Â | Â | Â | Â | Â | |
 TNM stage | (III vs. II) | 1.977 | 1.181 | 3.310 | 0.010 | |
 Microsatellite status | (MSI-H vs. MSS, MSI-L) | 0.231 | 0.072 | 0.738 | 0.013 | |
 SPINK4 expression | (high vs. low) | 0.462 | 0.210 | 1.018 | 0.056 | |
GSE39582 dataset | Univariate analysis | Â | Â | Â | Â | Â |
 Gender | (female vs. male) | 0.773 | 0.569 | 1.051 | 0.100 | |
 Age | (per year) | 1.024 | 1.011 | 1.037 | 0.000 | |
 TNM stage | (III-IV vs. I-II) | 2.033 | 1.644 | 2.513 | 0.000 | |
 MMR status | (dMMR vs. pMMR) | 0.808 | 0.488 | 1.340 | 0.410 | |
 TP53 status | (MT vs. WT) | 1.290 | 0.884 | 1.883 | 0.187 | |
 KRAS status | (MT vs. WT) | 1.347 | 0.989 | 1.834 | 0.059 | |
 BRAF status | (MT vs. WT) | 1.162 | 0.681 | 1.982 | 0.582 | |
 SPINK4 expression | (high vs. low) | 0.662 | 0.464 | 0.944 | 0.023 | |
Multivariate analysis | Â | Â | Â | Â | Â | |
 Age | (per year) | 1.025 | 1.012 | 1.039 | 0.000 | |
 TNM stage | (III-IV vs. I-II) | 1.921 | 1.406 | 2.625 | 0.000 | |
 KRAS status | (MT vs. WT) | 1.365 | 1.001 | 1.861 | 0.050 | |
 SPINK4 expression | (high vs. low) | 0.636 | 0.444 | 0.911 | 0.014 | |
TCGA dataset | Univariate analysis | Â | Â | Â | Â | Â |
 Gender | (female vs. male) | 0.884 | 0.593 | 1.318 | 0.545 | |
 Age | (per year) | 1.018 | 1.002 | 1.035 | 0.030 | |
 TNM stage | (III-IV vs. I-II) | 3.002 | 1.979 | 4.554 | 0.000 | |
 KRAS status | (MT vs. WT) | 1.416 | 0.610 | 3.288 | 0.418 | |
 Tumor deposits | (yes vs. No) | 1.752 | 0.854 | 3.594 | 0.126 | |
 Perineural invasion | (yes vs. No) | 1.938 | 0.981 | 3.826 | 0.057 | |
 Venus invasion | (yes vs. No) | 2.566 | 1.658 | 3.970 | 0.000 | |
 Pretreatment CEA level | (per ng/mL) | 1.001 | 1.001 | 1.002 | 0.000 | |
 Lymphatic invasion | (yes vs. No) | 2.140 | 1.393 | 3.287 | 0.001 | |
 Histological type | (mucinous adenocarcinoma vs. adenocarcinoma) | 1.374 | 0.802 | 2.352 | 0.247 | |
 SPINK4 expression | (high vs. low) | 0.479 | 0.321 | 0.714 | 0.000 | |
Multivariate analysis | Â | Â | Â | Â | Â | |
 Age | (per year) | 1.040 | 1.003 | 1.078 | 0.034 | |
 TNM stage | (III-IV vs. I-II) | 3.750 | 1.323 | 10.635 | 0.013 | |
 Perineural invasion | (yes vs. No) | 2.359 | 0.864 | 6.445 | 0.094 | |
 Venous invasion | (yes vs. No) | 2.773 | 1.066 | 7.217 | 0.037 | |
 SPINK4 expression | (high vs. low) | 0.301 | 0.116 | 0.785 | 0.014 |